News
-
Aug. 15, 2024EnPlusOne Biosciences to Collaborate with Wyss Institute on Up to $27 Million Agreement By ARPA-H to Develop Disease-Agnostic Immunotherapeutic RNA Platform
-
Aug. 13, 2024Nature Biotechnology publishes pivotal EnPlusOne paper on Template-Independent Enzymatic Synthesis of RNA Oligonucleotides
-
Jul. 09, 2024EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand
EnPlusOne, a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, revealed today that it had achieved the successful synthesis of the antisense strand of the commercially approved siRNA drug, Leqvio® (inclisiran), a treatment for hypercholesteremia (high-cholesterol). Licensed from Alnylam Pharmaceuticals, Inc. by Novartis, Leqvio® currently addresses a multi-million patient population.
-
May. 14, 2024EnPlusOne to Unveil Advances in Enzymatic RNA Synthesis at TIDES 2024
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that co-founder and Chief Scientific Officer Jonathan Rittichier, PhD, will be presenting recent advances in the company’s ezRNA™ platform at TIDES USA 2024 in Boston on Thursday, May 16, 2024 at 9am. The three day event, at the Hynes Convention Center, brings together scientists and companies focused on the use of oligonucleotides and peptides in therapeutics.
-
Mar. 05, 2024
EnPlusOne to Address Advances in Enzymatic RNA Synthesis at the 11th Annual Oligo Networking Conference
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024. The two-day event will feature speakers from companies across life sciences discussing opportunities and challenges associated with the use of oligonucleotides in R&D and manufacturing by biopharmaceutical companies.
-
Oct. 20, 2023EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, today announced that Daniel Wiegand, CEO, and Jonathan Rittichier, CSO, both co-founders of the company, will be participating in the 19th annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain, beginning October 22nd. The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
-
Feb. 10, 2023EnPlusOne Biosciences Expands Scientific Advisory Board with Dr. Jonathan Watts, Ph.D.
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board. Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field. His expertise will provide meaningful contributions as EnPlusOne continues to develop and scale its proprietary enzymatic RNA (ezRNA™) synthesis platform enabling next-generation solutions for emerging RNA therapeutics.
-
Dec. 19, 2022
Wyss Institute at Harvard University partners with Northpond Labs to launch RNA solutions company EnPlusOne Biosciences
Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and EnPlusOne Biosciences (EnPlusOne Bio) announced that the startup company has signed a worldwide, exclusive licensing agreement with Harvard’s Office of Technology Development (OTD) that grants EnPlusOne Bio the rights to commercialize a novel, controlled enzymatic RNA oligonucleotide synthesis technology. The “ezRNA” platform technology was invented and advanced by Wyss Core Faculty member George Church, Ph.D. and an expert team of biologists, chemists, and life science entrepreneurs at the Wyss Institute, and supported and funded by Northpond Labs, the research and development-focused affiliate of Northpond Ventures, as the inaugural project of the Wyss Institute Northpond Labs alliance.
-
Sep. 30, 2022
EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing. The round was led by Northpond Ventures with participation from Breakout Ventures, Coatue, and angel investors. The financing will support continued development and scaling of the company’s proprietary ezRNA™ synthesis platform in line with the company’s mission to enable next-generation solutions for emerging RNA therapeutics.
-
Sep. 01, 2022Daniel Wiegand on the RNA Revolution
We’re in the midst of an RNA revolution, and Daniel Wiegand and his team are prepared to deliver RNA to the world by making high-quality RNA oligonucleotides cheaper and more easily accessible. After an impactful co-op experience at a pharmaceutical company during his undergraduate years, Daniel understood what it truly meant to be a scientist, and he was hooked. His passion for cutting-edge, impactful science brought him to the Wyss, where he is leading the development of a manufacturing platform for the enzymatic synthesis of RNA oligonucleotides for use in therapeutics. Learn more about Daniel and his work in this month’s Humans of the Wyss.